FitOn HealthApril 236 min read

Exercise and GLP-1s: The Missing Piece in Your Employee Benefits Strategy

The connection between exercise and GLP-1s is one of the most important factors in whether your employees actually keep the results they gain on medication. Semaglutide and tirzepatide have delivered outcomes that weren't possible before: meaningful weight loss, improved metabolic markers, and a genuine shift in how people feel day to day.

The problem is, most employer benefits strategies are only funding half the equation. The medication handles appetite suppression and metabolic function, but exercise and structured lifestyle support are what the research consistently identifies as the difference between results that last and results that quietly unravel. Right now, most organizations aren't connecting those two things — and the cost of that gap shows up later, in regain, in returning comorbidities, and in a GLP-1 investment that doesn't hold its value over time.

If you're covering GLP-1 medications without pairing them with movement and strength support, this is what you need to know.

What GLP-1 Medications Do (And What They Don't)

GLP-1 receptor agonists work by mimicking a naturally occurring hormone that signals satiety to the brain. They slow gastric emptying, suppress appetite, and — in newer dual-agonist formulations — enhance metabolic effects. In large clinical studies, people using these therapies lose an average of 15% of their body weight over about 68 weeks. That's a level of results that wasn't achievable with lifestyle change alone.

The impact extends beyond the scale. Many people also see improvements in type 2 diabetes, blood pressure, and cardiovascular health — meaningful outcomes for both employees and the employers funding their care.

But here's what GLP-1s don't do:

Build or preserve muscle mass
Improve sleep quality or stress regulation
Teach sustainable nutrition habits
Increase cardiovascular fitness
Address the behavioral or environmental drivers of weight gain

Those are the domains of lifestyle intervention — and specifically, of consistent exercise and movement. Without them, the research is clear about what happens next.

The GLP-1 Muscle Loss Problem Employers Need to Know About

Here's the part that rarely makes it into the benefits conversation: a majority of the weight lost on GLP-1 medications isn't always fat. It can be muscle.

That distinction carries real consequences for your workforce. Less muscle means a slower resting metabolism, making it harder to sustain weight loss long-term. For employees over 40, that muscle loss compounds what the body is already losing naturally with age — raising the risk of injury, reduced mobility, and chronic pain. And when muscle decreases without regular movement to counter it, the body becomes more efficient at storing fat.

Leading health organizations now recommend resistance training as a standard part of any GLP-1 treatment plan for exactly this reason. Exercise and GLP-1s aren't separate tracks — they're designed to work together.

So the real question for your benefits strategy is this: are your employees getting moving while they're on these medications? Because if the answer is no, the investment you're making in GLP-1 coverage may be quietly working against itself.

The Real ROI of GLP-1s Depends on What Comes Next

GLP-1 medications are among the highest-cost pharmacy items in employer health plans. Annual spend per covered employee on average, ranges from $12,000 to $20,000 — and with utilization rising sharply (total GLP-1 spend increased approximately 50% in 2025), it's one of the fastest-growing line items in benefits budgets.

But the financial question isn't just what GLP-1s cost today. It's what discontinuation costs over time.

One of the most cited studies in this space followed participants one year after they stopped taking semaglutide. The finding was striking: patients regained approximately two-thirds of the weight they had lost. Blood pressure, blood sugar, and cholesterol all trended back toward baseline.

For employers, that pattern creates a predictable cost cycle. When GLP-1 therapy reduces obesity-related conditions — and then those improvements reverse after discontinuation — you're not just losing the benefit of the medication investment. You're also seeing the return of related illnesses that drive chronic disease spend: type 2 diabetes management, cardiovascular conditions, musculoskeletal issues, and mental health treatment. Obesity-related conditions already cost U.S. employers an estimated $13.4 to $26.8 billion annually in lost productivity, separate from direct healthcare costs.

The organizations getting the most durable ROI from GLP-1 coverage are those that have built lifestyle infrastructure — including movement and strength programming — before, during, and after medication use. So when the medication changes, the habits don't.

What the Research Says About Exercise and GLP-1s Together

The clinical case for pairing exercise with GLP-1 therapy isn't theoretical. It's consistent across studies.

Employees who combine GLP-1 medication with structured behavioral support — including regular movement — tend to lose more weight, sustain it longer, and see greater improvements across key health markers. Cardiovascular and metabolic outcomes are stronger when medication is paired with consistent physical activity. And engagement in lifestyle support helps employees manage common side effects and maintain adherence over time, both of which are critical to long-term success.

The lifestyle components research consistently identifies as highest-impact for GLP-1 users:

Resistance training — preserves and rebuilds lean muscle mass, maintains resting metabolic rate
Protein-forward nutrition — supports muscle retention and addresses micronutrient gaps common during reduced-calorie intake on GLP-1s
Sleep optimization — poor sleep elevates cortisol and ghrelin (the hunger hormone GLP-1s work to suppress), directly undermining medication effectiveness
Stress management — chronic stress promotes fat storage and emotional eating patterns that medication alone doesn't address
Cardiovascular fitness — improves heart health, insulin sensitivity, and energy, particularly important as weight loss naturally slows around the six-month mark

This isn't a nice-to-have list. It's the clinical foundation of what makes GLP-1 outcomes last — and it maps directly to what a comprehensive wellness benefit should be delivering.

Where Most GLP-1 Benefit Strategies Fall Short

Most employers are approaching GLP-1 coverage as a pharmacy decision. And that makes sense — that's where the cost lives. But the lifestyle side of the equation is where results either hold or reverse.

A few questions worth asking about your current strategy:

Are employees on GLP-1s proactively connected to fitness and nutrition resources — or only reactively, if they seek them out?
Does your wellness benefit include access to resistance training and strength-focused programming?
Is there a defined transition plan for employees tapering or stopping GLP-1 therapy?
Do you have a way to measure outcomes beyond weight — including fitness engagement, adherence, and claims trends for GLP-1 users?

If the answers are uncertain, the gap between what GLP-1s can deliver and what your benefit is currently set up to support is probably larger than it looks. For deeper context on the clinical and financial picture, the FitOn Health GLP-1 & The Lifestyle Gap guide breaks it down with the data.

FitOn Health Fills the Lifestyle Gap with Structured GLP-1 Exercise Support

FitOn Health is the all-in-one health and wellness benefit built to give your people the premium support GLP-1 medications can't provide on their own.

Our Weight Loss Companion Program is purpose-built for GLP-1 users — combining movement, nutrition, and whole-person well-being support into a structured program that helps employees stay active, eat well, and build sustainable routines that last beyond the medication. That includes the largest variety of in-person fitness experiences plus premium digital workouts (strength training, HIIT, yoga, and low-impact options), nutrition courses that address the specific dietary needs of GLP-1 therapy, and sleep and stress support that research links directly to sustained outcomes.

The result is a benefit that works with GLP-1 coverage — not alongside it as an afterthought — and gives you the outcomes data to see the difference.

Explore the Weight Loss Companion Program →